Christina U. Lorentz

The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial

Christina U. Lorentz, Erik I. Tucker, Norah G. Verbout et al. · Blood · 2021 · 112 citations · Full text

Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial

Christina U. Lorentz, Norah G. Verbout, Michael Wallisch et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2019 · 98 citations · Full text

Immunohematology, Immunology, Pharmacotherapy +20

ProNGF, a cytokine induced after myocardial infarction in humans, targets pericytes to promote microvascular damage and activation

Chia-Jen Siao, Christina U. Lorentz, Pouneh Kermani et al. · The Journal of Experimental Medicine · 2012 · 77 citations

Pro-nerve Growth Factor, Microvascular Damage, Immunology +22

Simple Scoring System to Predict In‐Hospital Mortality After Surgery for Infective Endocarditis

Giuseppe Gatti, Andréa Perrotti, Jean‐François Obadia et al. · Journal of the American Heart Association · 2017 · 75 citations · Full text

Inhibition of contact-mediated activation of factor XI protects baboons against S aureus–induced organ damage and death

Robert Silasi‐Mansat, Ravi S. Keshari, Cristina Lupu et al. · Blood Advances · 2019 · 74 citations · Full text